Clinical Trial

Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, Phase Ib/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10516 in combination with lenvatinib in patients with advanced clear cell renal cell carcinoma (ccRCC) who have progressed after receiving at least one prior line of systemic therapy. The study comprises two distinct phases: a dose exploration phase and a proof-of-concept phase.
Trial Details
NCT Number NCT07097935
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Advanced Clear Cell Renal Cell Carcinoma
Enrollment 104 participants
Start Date 2025-07-10
Primary Completion 2027-07-10 (estimated)
Study Completion 2028-07-10 (estimated)
Updated on ClinicalTrials.gov 2025-08-01